- Home
- CYTK
as of 11-28-2025 12:35pm EST
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 8.0B | IPO Year: | 2004 |
| Target Price: | $77.87 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.31 - $69.33 | Next Earning Date: | 11-05-2025 |
| Revenue: | $87,211,000 | Revenue Growth: | 2609.26% |
| Revenue Growth (this year): | 363.61% | Revenue Growth (next year): | 64.33% |
AI-Powered CYTK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
Director
Avg Cost/Share
$64.73
Shares
5,000
Total Value
$323,650.00
Owned After
22,933
SEC Form 4
EVP Research & Development
Avg Cost/Share
$66.45
Shares
2,200
Total Value
$146,190.00
Owned After
140,610
SEC Form 4
Director
Avg Cost/Share
$65.08
Shares
5,175
Total Value
$336,789.00
Owned After
9,977
SEC Form 4
EVP Research & Development
Avg Cost/Share
$59.55
Shares
2,295
Total Value
$136,667.25
Owned After
140,610
SEC Form 4
President & CEO
Avg Cost/Share
$62.86
Shares
5,000
Total Value
$314,300.00
Owned After
358,108
SEC Form 4
Director
Avg Cost/Share
$58.68
Shares
4,375
Total Value
$256,725.00
Owned After
32,444
SEC Form 4
EVP Research & Development
Avg Cost/Share
$58.22
Shares
2,105
Total Value
$122,553.10
Owned After
140,610
SEC Form 4
President & CEO
Avg Cost/Share
$60.03
Shares
5,000
Total Value
$300,150.00
Owned After
358,108
SEC Form 4
EVP Research & Development
Avg Cost/Share
$60.56
Shares
2,000
Total Value
$121,120.00
Owned After
140,610
SEC Form 4
Director
Avg Cost/Share
$60.00
Shares
6,757
Total Value
$405,420.00
Owned After
9,977
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| PARSHALL B LYNNE | CYTK | Director | Nov 19, 2025 | Sell | $64.73 | 5,000 | $323,650.00 | 22,933 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Nov 18, 2025 | Sell | $66.45 | 2,200 | $146,190.00 | 140,610 | |
| Kaye Edward M. MD | CYTK | Director | Nov 11, 2025 | Sell | $65.08 | 5,175 | $336,789.00 | 9,977 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Nov 4, 2025 | Sell | $59.55 | 2,295 | $136,667.25 | 140,610 | |
| Blum Robert I | CYTK | President & CEO | Oct 30, 2025 | Sell | $62.86 | 5,000 | $314,300.00 | 358,108 | |
| WIERENGA WENDELL | CYTK | Director | Oct 27, 2025 | Sell | $58.68 | 4,375 | $256,725.00 | 32,444 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 21, 2025 | Sell | $58.22 | 2,105 | $122,553.10 | 140,610 | |
| Blum Robert I | CYTK | President & CEO | Oct 16, 2025 | Sell | $60.03 | 5,000 | $300,150.00 | 358,108 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 7, 2025 | Sell | $60.56 | 2,000 | $121,120.00 | 140,610 | |
| Kaye Edward M. MD | CYTK | Director | Oct 6, 2025 | Sell | $60.00 | 6,757 | $405,420.00 | 9,977 |
Compare CYTK vs Leading Stocks
See how CYTK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.